Rhythm Pharmaceuticals, Inc. (RYTM)
| Market Cap | 1.51B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -132.06M |
| Shares Out | 44.14M |
| EPS (ttm) | -3.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $33.99 |
| Previous Close | $34.26 |
| Change ($) | -0.27 |
| Change (%) | -0.79% |
| Day's Open | 34.30 |
| Day's Range | 33.61 - 34.86 |
| Day's Volume | 203,094 |
| 52-Week Range | 13.16 - 34.86 |
BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare ge...
-- Study met primary endpoint and all key secondary endpoints with statistically significant and clinically meaningful reductions in weight and hunger -- -- All primary endpoint responders wer...
BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare ge...
Rhythm's (RYTM) stock gains as FDA approves its lead product candidate for chronic weight management.
-- Indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing -- -- Approv...
-- Interim d ata from Phase 2 study showed that once-weekly formulation of setmelanotide achieve d safety and efficacy results comparable to daily-dosing formulation -- -- Additional data from...
-- NDA for setmelanotide for POMC and LEPR deficiency obesities under review, with PDUFA goal date of November 27, 2020 -- -- Appointed Jennifer Chien and Yann Mazabraud to co-lead global int...
Largest studies in POMC and LEPR deficiency obesities demonstrate that treatment with setmelanotide reduced body weight and hunger Largest studies in POMC and LEPR deficiency obesities demonst...
BOSTON, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment...
Rhythm Pharmaceuticals (RYTM) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
– Company announces organizational changes designed to accelerate global strategy –
BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treat...
Rhythm (RYTM) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatm...
-- Appointed David Meeker, M.D., as President and Chief Executive Officer –
BOSTON, July 27, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatme...
BOSTON, July 20, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatme...
-- Study demonstrated that treatment with setmelanotide reduced body weight and hunger in individuals living with Bardet-Biedl syndrome -- BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Rhythm ...
BOSTON, July 01, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatme...
Rhythm's Setmelanotide Data And Other News: The Good, Bad And Ugly Of Biopharma
-- Once-weekly formulation of setmelanotide achieved weight loss efficacy comparable to daily-dosing formulation –
– FDA grants Priority Review of application and sets PDUFA goal date of November 27, 2020 –
Hunter Smith, Chief Financial Officer, appointed Interim Chief Executive Officer following completion of NDA submission to FDA
BOSTON, March 30, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treat...
BOSTON, March 18, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treat...
Shares of Rhythm Pharmaceuticals Inc. RYTM, -2.64% were down 3% in trading on Tuesday, the day after the company announced that president and CEO Keith Gottesdiener plans to step down.
Keith Gottesdiener, M.D. to Step Down as Chief Executive Officer Following NDA Submission for Setmelanotide in POMC and LEPR Deficiency Obesities Expected in the First Quarter of 2020
-- Topline data expected in the fourth quarter of 2020 or early in the first quarter of 2021 -- -- Supplemental cohort continues enrollment to meet patient demand --
Rhythm Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
BOSTON, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the tre...
BOSTON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the tre...
BOSTON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the tre...
Liver Therapy Forum weekly digest provides an overview of what's happening in therapeutics for obesity in 2019. The focus this week is Rhythm Pharmaceuticals.
-- Four new MC4R pathway obesity indications added to Phase 2 Basket Study and enrolling patients -- -- Genetic sequencing of 13,567 individuals with severe obesity yields 11.7 percent (1,5...
-- Plan to expand ongoing Phase 2 Basket Study with four additional rare indications -- -- Sequenced nearly 14,000 people with early-onset, severe obesity; Yield suggests potential significant...
BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare...
About RYTM
Rhythm Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2... [Read more...]
| Industry Biotechnology | IPO Date Oct 5, 2017 |
| CEO Keith Gottesdiener | Employees 70 |
| Stock Exchange NASDAQ | Ticker Symbol RYTM |
Analyst Forecasts
According to 8 analysts, the average rating for RYTM stock is "Buy." The 12-month stock price forecast is 35.75, which is an increase of 5.18% from the latest price.